A2734

α5IA

≥98% (HPLC)

• Sinónimos: 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-, 3-(5-Methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methoxy-1,2,4-triazolo[3,4-a]phthalazine
• Fórmula empírica (notación de Hill): C₁₇H₁₄N₈O₂
• Número de CAS: 215874-86-5
• Peso molecular: 362.35
• Número MDL: MFCD09832717
• Código UNSPSC: 12352200
• ID de la sustancia en PubChem: 329770794
• NACRES: NA.77

Propiedades

• Ensayo: ≥98% (HPLC)
• Formulario: powder
• color: off-white to light yellow
• solubilidad: DMSO: >2 mg/mL
• emisor: Merck & Co., Inc., Kenilworth, NJ, U.S.
• temp. de almacenamiento: 2-8°C
• cadena SMILES: Cc1cc(no1)-c2nnc3c4ccccc4c(OCc5cn(C)nn5)nn23
• InChI: 1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
• Clave InChI: NZMJFRXKGUCYNP-UHFFFAOYSA-N

Descripción

Acciones bioquímicas o fisiológicas

α5IA is a selective inverse agonist for Α5 subtype of GABAA receptor with a higher intrinsic activity at the A5 subtype than other drugs. α5IA enhances cognition in laboratory animals without being proconvulsant or anxiogenic. α5IA acts as an "alcohol antagonist," markedly reducing the amnesic effect of alcohol and partially attenuating sedation, similar to Ro15-4513, but without the anxiogenic effect. α5IA offers promise as a tool to study cognitive disorders, memory function, and treatment of alcohol-related disorders.

α5IA is a selective inverse agonist for a5 subtype of GABAA receptor.

Características y beneficios

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Código de clase de almacenamiento: 13 - Non Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: Eyeshields, Gloves, type N95 (US)